• Our Science

    Programs developing molecules to amplify immune recognition of cancers

  • Clinical Trials

    Targeting various cancers either in monotherapy or in combination

  • Working at iTeos

    Recruiting top talent for both our US and Belgium sites

Pipeline

iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.

The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.

Learn more about our pipeline
Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Phase 2/3
Inupadenant
Monotherapy Solid tumors
+ pembrolizumab Anti-PD-1-Resistant Melanoma
+ pembrolizumab Castrate-Resistant Prostate Cancer
+ paclitaxel carboplatin Triple-Negative Breast Cancer
EOS-448
Dose Finding, PK/PD Solid tumors
+ IMID Multiple Myeloma
+ pembrolizumab Solid Tumors
+ Inupadenant Solid Tumors
Adenosine Pathway Inhibitor
Oncology

Our latest news

  • iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

    EOS-448 is currently in phase I for advanced solid tumours with a randomised PD-1 combination study planned for 2022 iTeos to receive a $625 million upfront payment in addition to potential milestones, and royalty payments on ex-US sales GSK and iTeos will co-commercialise and share profits in the

  • iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

    Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor resistant

  • iTeos to Present at the Jefferies Virtual Healthcare Conference

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Reports First Quarter 2021 Financial Results and Provides Business Update

    - Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 - - Inupadenant updated monotherapy clinical data and evidence of association of A 2A receptor expression with

  • iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 06, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

    Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a

  • iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    – Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results – – Updated, single-agent data of inupadenant (EOS-850) from Phase 1/2a trial and initial